secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001493152-26-007965
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Technologies announces validation study with Brooke Army Medical Center for CyPath Lung test
--------------------------------------------------------------------------------

- Study with BAMC to validate CyPath Lung on sputum obtained by tracheal/bronchial suctioning for early lung cancer detection.
- Enrolling 30-50 patients; results expected by mid-2026.
- Potential to expand sample collection options; currently patients collect sputum at home.
- U.S. bronchoscopy procedures ~500,000 annually; market valued at $700-920M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226007965/0001493152-26-007965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226007965/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-007965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer